Bronchitis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Bronchitis Treatment Market is Segmented By Disease Type (Viral bronchiolitis, Bronchiolitis obliterans), By Treatment (Medication (Anti-Inflammatory Drugs, Antibiotics, Bronchodilators, Mucolytic, Others), Oxygen Therapy, Others), By Age Group (Young children, Infants, Adults), By Sales Channel (Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users (Hospitals, Specialty Clinics, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Bronchiolitis Treatment Market Overview

Global Bronchiolitis Treatment Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.

Bronchiolitis is a common lower respiratory tract infection that affects young children, often caused by a viral infection, most commonly respiratory syncytial virus (RSV). Bronchitis is often treated with supportive care that focuses on symptom relief and making sure the child gets enough oxygen and fluids. Although bronchiolitis typically only causes a minor illness, severe cases can lead to lung failure.

The most typical lower respiratory tract infection in children under the age 2 is bronchiolitis. The bronchiolitis-causing viruses are spread by contact. Saliva or mucus from the lips or nose are respiratory droplets that these viruses can transmit through. These droplets are airborne and spread from person to person when someone sneezes or coughs, or they can attach to frequently touched items or surfaces. 

Bronchiolitis Treatment Market Scope

For more details of the report, Request for sample

Market Dynamics: Drivers and Restraints

The rising incidence of respiratory syncytial virus (RSV)

The respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis. RSV is a highly contagious virus that affects the respiratory system, specifically the bronchioles or small airways, causing swelling and congestion. It is the main reason why newborns and young children get bronchiolitis. One of the main factors propelling the market for bronchiolitis treatment is the rising incidence of respiratory syncytial virus (RSV) infection. 

For instance, according to American Medical Association, stated that each year in United States, RSV leads to approximately 2.3 million outpatient (non-hospitalization) visits among children younger than 5 years old and about 58,000-80,000 hospitalizations among children younger than 5 years old.

Seasonal respiratory virus outbreaks, especially respiratory syncytial virus (RSV), a prominent cause of bronchiolitis, can also have a considerable effect on the market. The need for diagnostic equipment, antiviral drugs, and supportive care goods rises during outbreaks. The diagnosis and management of bronchiolitis have improved because to developments in medical technology, such as the creation of quick diagnostic tests to identify viral infections. Innovative medical treatments and products have the potential to expand markets.

Market Dynamics: Restraint

The bronchiolitis market may be constrained by a number of conflicts. These elements may hinder the development of the market and have an impact on the adoption of treatments and related products as well as their development and marketing. For instance, there aren't many antiviral medications specifically for bronchiolitis. Particularly in the absence of pharmaceuticals that are universally beneficial, the lack of tailored therapy can impede market expansion. Furthermore, hospitalisation, medical equipment, and supportive care might come at a high expense in situations of severe bronchiolitis. High treatment costs can impede market expansion and restrict access to healthcare, particularly in developing countries.

Bronchiolitis Treatment Market Segmentation

The global bronchiolitis treatment market is segmented based on disease type, treatment, age group, sales channel  and region.

The bronchiolitis obliterans segment from the type segment accounted for approximately 41.7% of bronchiolitis treatment type share

The severe lung condition bronchiolitis obliterans, also known as obliterative bronchiolitis or constrictive bronchiolitis, is defined by inflammation and scarring of the tiny airways in the lungs (bronchioles). It becomes more difficult for air to enter and exit the lungs as a result of the condition's gradual constriction and obstruction of these airways. 

For the purpose of creating efficient cures and treatments for bronchiolitis obliterans, research is vital. To advance medical interventions and enhance the quality of life for those who are affected, it is essential to comprehend the illness mechanisms, discover biomarkers, and investigate prospective therapeutic targets. Therefore, the increase of study and developments on bronchiolitis obliterans helps. 

Thus rise of research and developments on bronchiolitis obliterans helps to boost the segment growth. For instance, In May 2023, Zambon completes enrollment in the Phase 3 Clinical Development Programme evaluating liposomal cyclosporine A for inhalation (L-CsA-i) in BOS patients. The company's aim of providing a much needed therapy to lung transplant recipients globally with BOS is one step closer with the conclusion of enrolment in the company's crucial trials. Thus, the aforementioned factors boost segment expansion.

Bronchiolitis Treatment Market Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

North America currently controls the market for bronchiolitis drugs in terms of market share and revenue, and this dominance will only increase during the anticipated time period. This is owing to the presence of large key competitors and the fact that the market in that region will continue to expand quickly as a result of rising healthcare expenditures. Additionally, the region's expansion is supported by the rise in product approvals by governmental or medical agencies.

For instance, on July 17, 2023, parents currently had a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common germ that hospitalizes as many as 3% of children under the age of 1 in the United States each year. The U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of RSV in newborns and infants born during or entering their first RSV season.

In addition, Asia-Pacific will be growing over the projection period due to the region's rising prevalence of inflammatory respiratory diseases. The growth rate of the market in this region will also be further accelerated by the development of the healthcare infrastructure.

COVID-19 Impact Analysis

Healthcare resources were redirected to handle a rise in COVID-19 cases at the height of the COVID-19 epidemic. The overcrowding in hospitals and healthcare institutions made it difficult to provide patients with bronchiolitis with the best care possible. For COVID-19 patients, resources like medical personnel, hospital beds, and medical equipment were given priority.

For fear of exposing their kids to the virus, many parents and other carers were reluctant to bring their kids to clinics and hospitals. This hesitation reduced hospital admissions for bronchiolitis and other disorders unrelated to COVID-19, which had an effect on the demand for therapies for bronchiolitis. 

Some kids who had COVID-19 continued to have respiratory issues. This sparked worries about potential long-term respiratory problems, such as symptoms similar to bronchiolitis, which may have an effect on the market for bronchiolitis therapies in the future.

Competitive Landscape

The major global players in the market include Sanofi, GlaxoSmithKline Inc, Taj Pharmaceuticals Limited, Avalon Pharma Private Limited, AstraZeneca, Mylan N.V., Inogen, Inc, Invacare Corporation, CAIRE Inc, Drive DeVilbiss International and among others.

Key Developments

• On January 5, 2023, Biologics Licence Application (BLA) for nirsevimab had been approved by the U.S. Food and Drug Administration (FDA) Centre for Drug Evaluation and Research (CDER) for the treatment of children up to 24 months old who are still susceptible to developing severe respiratory syncytial virus (RSV) disease during the second RSV season as well as for newborns and infants entering or currently undergoing their first RSV season.
• On August 25, 2022, regarding its bivalent RSV prefusion F vaccine candidate, RSVpreF, Pfizer Inc. published beneficial top-line data from the Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunised against RSV disease).

Why Purchase the Report?

• To visualize the global bronchiolitis treatment market segmentation based on disease type, treatment, age group, sales channel and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of bronchiolitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bronchiolitis treatment market report would provide approximately 69 tables, 63 figures and 177 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies